Announcements
- First Quarter 2024: Strong growth in US sales of The NGAL Test
- Resolutions of Annual Geneal Meeting
- Grant of warrants
- BioPorto A/S Appoints Chief Legal Officer
- New Board Candidate for the upcoming Annual Geneal Meeting
- Notice convening the Annual General Meeting in BioPorto A/S
- Correction: BioPorto Announces Annual Results for 2023
- BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer
- BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-2026
- Roche Diagnostics and BioPorto expand collaboration
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 379.67m |
Free float | 338.56m |
P/E (TTM) | -- |
Market cap | 675.05m DKK |
EPS (TTM) | -0.1501 DKK |
Data delayed at least 15 minutes.
More ▼